Breaking News Instant updates and real-time market news.

TNXP

Tonix Pharmaceuticals

$3.15

-0.14 (-4.26%)

16:56
08/11/17
08/11
16:56
08/11/17
16:56

Tonix Pharmaceuticals files $150M mixed securities shelf

TNXP Tonix Pharmaceuticals
$3.15

-0.14 (-4.26%)

09/07/16
CANT
09/07/16
DOWNGRADE
CANT
Hold
Tonix Pharmaceuticals downgraded to Hold from Buy at Cantor
Cantor analyst Chiara Russo downgraded Tonix after its TNX-102 SL drug missed its primary endpoint in a Phase 3 study of fibromyalgia patients, and the company decided to no longer pursue the fibromyalgia endpoint. Russo notes that the company now plans to pursue PTSD as the lead indication, but the analyst continue to "remain cautious" on that indication. Target to $1 from $5.
09/07/16
ROTH
09/07/16
DOWNGRADE
Target $1.25
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded Tonix Pharmaceuticals to Neutral from Buy as he re-evaluates its PTSD program given that it is now the primary lever for the shares after the company reported that Tonmya phase 3 data to treat fibromyalgia did not achieve its primary endpoint. The analyst also lowered his price target on the shares to $1.25 from $7.5.
09/07/16
OPCO
09/07/16
DOWNGRADE
OPCO
Perform
Tonix Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Tonix after its TNX-102 SL drug missed its primary endpoint in a Phase 3 study of fibromyalgia patients, and the company decided to no longer pursue the fibromyalgia endpoint.
06/26/17
AGIS
06/26/17
INITIATION
Target $10
AGIS
Buy
Tonix Pharmaceuticals initiated with a Buy at Aegis
Aegis analyst Robert LeBoyer initiated Tonix Pharmaceuticals with a Buy and a $10 price target saying its lad product, TNX-102 SL, is asublingual transmucosal formulation of cyclobenzaprine that recently began a Phase3 trial for posttraumatic stress disorder. The analyst expects full enrollment by year-end 2018, results in 2019, and approval by mid-2020, and assumes earnings of $1.96 for FY2021.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.